Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial
Authors: Julio Rosenstock, MD1, Rifat Emral, MD2, Leobardo Sauque-Reyna, MD3, Viswanathan Mohan, MD4, Carlos Trescolí, MD5, Saud Al Sifri, MD6, Nebojsa Lalic, MD7, Agustina Alvarez, MD8, Pascaline Picard, MSc9, Mireille Bonnemaire, MD10, Nacima Demil, MD11, Rory J. McCrimmon, MBChB12, on behalf of the SoliMix Trial Investigators
Affiliations: 1Dallas Diabetes Research Center at Medical City, Dallas, TX, USA; 2Department of Endocrinology and Metabolic Diseases, Ankara University Faculty of Medicine, Ankara, Turkey; 3Instituto de Diabetes Obesidad y Nutrición S.C., Cuernavaca, Morelos, Mexico; 4Dr. Mohan’s Diabetes Specialities Centre & Madras Diabetes Research Foundation, IDF Centre of Excellence in Diabetes Care & ICMR Centre for Advanced Research on Diabetes, Chennai, India; 5Hospital Universitario de La Ribera, Alzira, Spain; 6Al Hada Military Hospital, Taif, Saudi Arabia; 7Faculty of Medicine of the University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia; 8Sanofi, Buenos Aires, Argentina; 9IVIDATA Life Sciences, Levallois-Perret, France; 10Sanofi, Paris, France; 11Diabetes Medical Operation Department, Sanofi, Chilly-Mazarin, France; 12Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, UK
Information is provided for scientific purposes only and may be outside the current labelling of the product. Sanofi does not recommend the use of any products in any manner inconsistent with that described in the full prescribing information. Please consult the prescribing information in your country of practice, as it can vary from country to country.
Availability of posters and/or abstracts on this site will coincide with ADA’s embargo policy.